Who is sponsoring NCT05378438?

NCT05378438 is sponsored by Nepal Health Research Council.

What drugs are being tested in NCT05378438?

Interventions in NCT05378438: Microbe literacy Program in the form of workshop.

What condition does NCT05378438 study?

NCT05378438 studies Vaccine Acceptance.

Is NCT05378438 still recruiting?

NCT05378438 is currently status unknown. Last updated 6 July 2022.

Last reviewed 2022-07-06 · How we verify

NCT05378438

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Microbe Literacy Initiative on Improved Vaccine Uptake in Peri-urban Slum Areas in Kathmandu, Nepal

Status unknown NA Last updated 6 July 2022

What this trial tests

NA trial testing Microbe literacy Program in the form of workshop in Vaccine Acceptance in 1,252 participants. Status unknown.

Timeline

15 July 2022

Primary endpoint
30 September 2022

17 April 2023

Quick facts

Lead sponsor	Nepal Health Research Council
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	1,252
Start date	15 July 2022
Primary completion	30 September 2022
Estimated completion	17 April 2023
Sites	1 location across Nepal

Drugs / interventions tested

Microbe literacy Program in the form of workshop

Conditions studied

Vaccine Acceptance — all drugs for Vaccine Acceptance →

Sponsor

Nepal Health Research Council

Who can join

18 and older, any sex, with Vaccine Acceptance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to assess the impact of the first introduction of microscope-based health education on people's attitude and practice towards disease prevention in Nepal, measured by vaccine acceptance rate. Such health education has an important role to play in communities where vaccine acceptance is low.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Nepal Health Research Council trials

Trials by the same sponsor.

NCT05259735 — A Clinical Guideline-based Management of Type-2 Diabetes by Ayurvedic Practitioners in Nepal · NA · completed
NCT04733651 — Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19 · Phase 2 · unknown
NCT04694612 — Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal · Phase 3 · unknown
NCT04669990 — Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study · unknown
NCT06189768 — A Study on Pigmentation Disorders in Children · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05378438 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nepal Health Research Council
Last refreshed: 6 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05378438.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing